Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.

Our US Research & Development hub, located in the Greater Boston area, brings together the best talent to drive life science innovation. Located in Lexington, Watertown and Cambridge, our teams reflect the full scope of R&D, from early research through late-stage clinical development. We are building for the future by creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research across multiple modalities and therapeutic areas. We recognize that improving human health starts here and that patients rely on us. By combining the speed and agility of biotech with the quality, resources, and stability of a large pharmaceutical company, our US R&D hub will benefit from the best of both worlds to develop new medicines that meet the needs of patients.

Across Novo Nordisk, our people wake up every day knowing their work matters.
From the researcher analysing data, to the manufacturing specialist ensuring quality in every single dose, to the sales professional making sure our treatments reach the people who need them – our people share something powerful: the collective belief that science and innovation can truly transform lives.
It’s not always easy. Breakthroughs take years. Setbacks happen. But knowing that your work could bring hope to millions living with serious chronic diseases. That’s what keeps us going - driving lasting change for long-term health.

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
75 Hayden Avenue
Lexington, MA 02421
  • Featured Employer
NEWS
Following the recommendations of an independent Data Monitoring Committee, Novo Nordisk has halted a Phase III kidney outcomes study of semaglutide ahead of schedule due to strong efficacy signals.
The class of drugs, which includes Novo Nordisk’s Ozempic and Wegovy, are associated with the risk of gastrointestinal adverse events when used for weight loss, finds a study published Thursday in JAMA.
Despite lawsuits by some companies challenging the negotiations under the Inflation Reduction Act, the manufacturers of the first 10 drugs selected for Medicare price talks will participate in the program.
Two Democratic senators on Thursday sent a letter to the companies’ CEOs informing them that they have until Sept. 15 to disclose the application processes for their insulin assistance programs.
With a recent study yielding positive results, experts say GLP-1 drugs are making headway in treating Alzheimer’s and other neurodegenerative diseases.
This is the Danish company’s second obesity-focused acquisition in three weeks. Under the deal, Novo Nordisk receives the full rights to develop and commercialize Embark’s lead metabolic platform.
A second trial shows Novo Nordisk’s Wegovy improves heart health. Meanwhile, many other drugs are beginning to face generic competition, including from newly approved biosimilars.
Wegovy’s highest dose significantly improved physical function and quality of life in obese patients with heart failure, according to results published Friday in The New England Journal of Medicine.
The Danish drugmaker is leveraging Thermo Fisher Scientific as Wegovy demand surges and amid production problems with manufacturer Catalent, Reuters reported on Wednesday.
JOBS
IN THE PRESS